*Stanford Center of Excellence for Sleep Disorders, Stanford, CA; †Neurology Consultants PC, Tuscaloosa, AL; and ‡Neurosciences MDC, GlaxoSmithKline, Research Triangle Park, NC.
Address correspondence and reprint requests to Clete A. Kushida, MD, PhD, RPSGT, Stanford Center of Excellence for Sleep Disorders, 401 Quarry Road, Suite 3301-A, Stanford, CA 94305-5730; E-mail: [email protected]
This study was supported by GlaxoSmithKline Research and Development.
Dr Kushida received financial support for research activities from GlaxoSmithKline, Xenoport, Pfizer, Boehringer-Ingelheim, and Schwartz Pharmaceuticals.
Dr Geyer received personal compensation from GlaxoSmithKline for serving on their scientific advisory board and their speakers' bureau. He is also on the speakers' bureau for Cephalon and Boehringer-Ingelheim. He has been involved in pharmaceutical trials with GlaxoSmithKline, Cephalon, Schwarz Biosciences, Kyowa Pharmaceuticals, and Pfizer.
Dr Tolson and Ms Asgharian are employees of GlaxoSmithKline.